Portfolio

Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of effector cytotoxic T and NK cells. These cells can be specifically targeted as they express the receptor KLRG1 (killer cell lectin-like receptor G1).

Adcendo ApS

Adcendo ApS is a biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers

ADCYTHERIX

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.

Adicet Bio

Adicet Bio is a bio-pharmaceutical company focused on the development of next-generation cell immunotherapies for the treatment of cancer. In January 2016, Adicet Bio acquired Applied Immune Technologies (“AIT”) which develops T-cell receptor (TCR) mimicking antibodies.

AgomAb Therapeutics

AgomAb is developing antibody therapies that induce regeneration of damaged tissues, including fibrosis.

Allena Pharmaceuticals

Allena Pharmaceuticals (NASDAQ:ALNA) is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.

Anaveon

Anaveon is a clinical stage company committed to transforming immunological insights into life-saving therapies. With a vision to use our expertise in cutting-edge immunology to design and develop treatments that benefit patients and society, the team has the skills to make it happen and is ready to see the impact of ANV419 in patients.

Antios Therapeutics

Antios Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.

ARMGO

Armgo is a small molecule therapeutics company developing first-in-class RyR1/2 modulators for the treatment of cardiac, musculoskeletal and neurological disorders.

ArQule

ArQule is a bio-pharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.

CathWorks

CathWorks is developing an image-based functional flow reserve (FFR) measurement during coronary catheterization, replacing the pressure-wire based, drug-induced measurement currently performed. CathWorks angiogram-based FFR (FFRangio) has met the need for a less invasive FFR assessment tool, to improve real-time functional assessment leading to treatment decisions, and to make coronary catheterization procedures safer, shorter, more accurate and comprehensive.

cCAM Biotherapeutics

cCAM Biotherapeutics develops novel immunotherapies for cancer. cCAM’s lead agent, CM-24, is an immunomodulatory antibody that blocks a novel immune checkpoint, thereby harnessing  the patient’s immune system to attack tumors. In July 2015, the company was acquired by Merck.

Check-Cap

Check-Cap is developing a solution for Colorectal Cancer Screening. The Check-Cap pill requires no unpleasant bowel preparation or invasive procedures and is expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy.

CytoReason

CytoReason is a technology company advancing pharmaceutical R&D through practical application of computational cell-level models of the human body.

Dynacure

Dynacure is a biotechnology company developing antisense drugs for Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals focuses on the discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations.

Emergence Therapeutics

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugate (ADC) immuno-therapeutics to treat high-need cancers. Our lead program features innovative antibody design as well as state-of-the-art linker and payload technology to target Nectin-4– an important and validated target for a broad range of cancers. The company was acquired by Lilly in 2023.

Enlivex Therapeutics

Enlivex Therapeutics is developing cell-based therapies for the induction of immune tolerance. Its lead program is in clinical development for graft-versus-host disease.

Eyevensys

Eyevensys develops non-viral gene therapy treatments for ophthalmology.

EyeYon

EyeYon Medical develops innovative medical devices for the treatment of corneal edema.

Fore Bio

Fore Bio identifies tumor-specific driver mutations, based on a functional assay that detects dysregulated signaling in cancer cells.

ForSight VISION6 Inc

V6 is developing an accommodating intraocular lens for placement in patients’ eyes post-cataract surgery.

Graviton Bioscience Corporation

Graviton is developing selective ROCK2 inhibitors for fibrotic and autoimmune indications. The company’s lead asset is GV101, a highly potent and selective ROCK2 inhibitor. It has demonstrated broad therapeutic potential across multiple in-vitro and in-vivo disease models including Graft Versus Host Disease (GVHD) as well as Idiopathic Pulmonary Fibrosis (IPF).

IMEL Biotherapeutics

IMEL Biotherapeutics is developing a cell-based therapy that represents a new paradigm for the treatment of patients with mitochondrial disorders. Using its proprietary Mitochondrial Replaced Cells technology, IMEL will enable the treatment of multiple patients with mitochondrial genetic or age-related disorders.

Download IMEL’s company profile

Immunic Therapeutics

Immunic Therapeutics is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

Kamari Pharma

Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule (SMC) inhibitors of TRPV3, a cation channel expressed primary in keratinocytes, for the treatment of dermatological conditions with unmet need.

Click here to read Kamari’s Profile

Keros

Keros is a biopharmaceutical company focused on treatments for rare muscle diseases. Its lead program is a small molecule for the treatment of FOP, an ultra-rare skeletal disease.

Kite Pharma

Kite Pharma is a publicly traded, clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T-cell therapy (CARs and TCRs), designed to restore the immune system’s ability to recognize and eradicate tumors.

LB Pharmaceuticals

LB Pharmaceuticals is a development-stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. LB’s approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs.

Levation

Levation is developing a topical Oxymetazoline for cosmetic eye lifts.

LogicBio

LogicBio is developing its proprietary gene therapy platform in order to provide lifelong cures for serious, early-onset rare diseases by combining the best of gene therapy and gene editing. Its GeneRide™ technology enables nuclease-free and promoterless site-specific integration of a therapeutic gene into the genome, allowing durable gene expression in dividing cells.

Lutris Pharma

utris-Pharma is developing LUT014, a topical B-Raf Inhibitor, a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to patients without interruptions caused by typical cutaneous side effects.

Mereo BioPharma

Mereo BioPharma is developing and commercializing new therapies for oncology and rare diseases, focusing on bone/musculoskeletal, respiratory and endocrine indications.

Metabomed

Metabomed is a drug discovery company in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. Metabomed focuses on targets which are synthetically lethal for biomarker- defined tumors.

Nuvectis Pharma

Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on the development of targeted therapies for the treatment of cancer.

OCON Medical

OCON Healthcare is developing a drug-device Bioconvergence platform to deliver drugs to the uterus on an innovative, smart 3D carrier.

Opiant

Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.

Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide, as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).

PACT Pharma

PACT Pharma is a bio-pharmaceutical company focused on the development of personalized T cell therapies targeting neo-antigens for as cancer treatments.

Precirix

Precirix (Formerly Camel-IDS) is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

Prevail Therapeutics

Prevail is developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases

ProQR

ProQR is an RNA therapeutics platform focused on rare inherited retinal diseases of childhood.

Protalix

Protalix is a biopharmaceutical company that specializes in the manufacture of recombinant therapeutic proteins through its ProCellEx plant cell-based protein expression system. Using ProCellEx, Protalix is developing a proprietary pipeline of biobetter and biosimilar recombinant proteins that target large, established markets and that rely upon known biological mechanisms of action.

Raziel Therapeutics

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for the treatment of local fat reduction. The company is targeting obesity and related indications.

ReWalk

The ReWalk™ is a robotic exoskeleton that allows paraplegics to bring walking into their daily lives once again. Culminating over a decade of research and development, the ReWalk system represents the first truly practical, real-world, walking solution for people with lower limb disabilities.

Saniona

Saniona is a rare disease biopharmaceutical company focused on research, development, and commercialization of treatments for the central nervous system. 

Silverback Therapeutics

Silverback is developing next-generation antibody-drug conjugates as immuno-oncology treatments for cancer.

Soligenix

Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

Stargazer Pharmaceuticals

Stargazer Pharmaceuticals is an ophthalmic biotech company focused on the development of a novel treatment option for Stargardt’s disease, a genetic orphan retinal disease with significant unmet medical needs.

Step Pharma

Step Pharma is a biotechnology company discovering and developing proprietary small molecule therapeutics for the treatment of auto-immune diseases. Step’s lead program is selective modulators against specific immune cell populations which are the main drivers of auto-immune diseases.

Stimatix

Stimatix is developing the Stimatix GI AOS (Artificial Ostomy Sphincter) series, a product line with unique ostomy appliances that improves the quality of life for individuals with stomas.

Stride Bio

Stride’s novel gene therapy pipeline targets diseases with significant unmet need and is designed to overcome the current limitations of first-generation gene therapies, with a current focus on rare disorders.

Sweetch

Sweetch is developing a telemedicine platform for outcome prediction and clinical intervention in diabetics.

TargEDys

TargEDys develops microbiome-based treatments for eating disorders and weight management.

UroGen

UroGen is a clinical-stage specialty pharmaceutical company focused on developing innovative sustained-release formulations for uro-oncology.

V-Wave

V-Wave has developed a miniature valve, which is implanted by catheterization into the left ventricle of the heart, to reduce the pressure on the muscle by controlling the blood flow between the heart chambers in patients who are frequently hospitalized with heart attacks.

Vanqua Bio

Founded in 2019, Vanqua Bio is a biopharmaceutical company focused on discovering and developing next-generation medicines for neurodegenerative diseases.  Our novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to advance needed therapies. Our lead program targets glucocerebrosidase (GCase) as a potential treatment for Parkinson’s disease (PD) and all forms of Gaucher disease (GD). Additional programs address overactivation of the innate immune system in central and peripheral neurodegenerative disorders, including Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease.

Vascular Graft Solutions

VGS is focused on the development and commercialization of innovative technologies for coronary and peripheral revascularization surgeries.

VBI Vaccines

VBI Vaccines is a commercial-stage biopharmaceutical company developing next generation vaccines to address unmet needs in infectious diseases and immuno-oncology.